Literature DB >> 10936696

Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain.

C J LaBuda1, P N Fuchs.   

Abstract

A behavioral test paradigm that measures the aversive quality of stimulus-evoked pain in an animal model of neuropathic pain (L5 ligation) was tested for sensitivity to (1) different forces (476 and 202 mN) and frequencies (once every 15 or 30 s) of mechanical stimulation to the hyperalgesic paw and (2) different doses of the common antinociceptive compounds morphine (1 and 10 mg/kg) and gabapentin (30 and 90 mg/kg). Compared to non-ligated controls, the greater force (476 mN) and frequency (every 15 s) of mechanical stimulation of the hyperalgesic paw was associated with the greatest degree of escape/avoidance behavior. There was not a significant degree of escape/avoidance behavior at the lowest force (202 mN) and frequency (every 30 s) of mechanical stimulation. Compared to ligated vehicle treated controls, morphine (1 mg/kg) and gabapentin (90 mg/kg) decreased mechanical hyperalgesia and also attenuated the escape/avoidance behavior. The antinociceptive and antiaversive effects were found at doses that did not produce evidence of decreased motor activity. It is concluded that the behavioral test paradigm used to measure the aversiveness of stimulus-evoked nociceptive behavior is sensitive to different degrees of evoked pain and traditional analgesic compounds.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936696     DOI: 10.1016/s0304-3940(00)01340-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  Behavioral assessments of the aversive quality of pain in animals.

Authors:  Xu-Jie Zhang; Tian-Wei Zhang; San-Jue Hu; Hui Xu
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

Review 2.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 3.  Cortico-limbic pain mechanisms.

Authors:  Jeremy M Thompson; Volker Neugebauer
Journal:  Neurosci Lett       Date:  2018-11-29       Impact factor: 3.046

4.  GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.

Authors:  Stacey C LaGraize; Perry N Fuchs
Journal:  Exp Neurol       Date:  2006-12-04       Impact factor: 5.330

Review 5.  Pharmacologic treatment of neuropathic pain.

Authors:  M S Wallace
Journal:  Curr Pain Headache Rep       Date:  2001-04

6.  Effects of morphine on thermal sensitivity in adult and aged rats.

Authors:  Drake Morgan; Jeremiah D Mitzelfelt; Lorraine M Koerper; Christy S Carter
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-12-21       Impact factor: 6.053

7.  Sensorimotor Activity Partially Ameliorates Pain and Reduces Nociceptive Fiber Density in the Chronically Injured Spinal Cord.

Authors:  Christopher Sliwinski; Timo A Nees; Radhika Puttagunta; Norbert Weidner; Armin Blesch
Journal:  J Neurotrauma       Date:  2018-06-29       Impact factor: 5.269

8.  Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain.

Authors:  Jun-Xu Li; David A Thorn; Yanyan Qiu; Bi-Wen Peng; Yanan Zhang
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

9.  Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder.

Authors:  Don R Cherek; Oleg V Tcheremissine; Scott D Lane; Cynthia J Pietras
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

10.  Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain.

Authors:  Louise H Pedersen; Gordon Blackburn-Munro
Journal:  Psychopharmacology (Berl)       Date:  2006-02-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.